Pavan P. Shah

Pavan P. Shah

Auto-generated profile, based on publicly available information

Pavan P. Shah

Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in World Neurosurgery
Verified
Journal Article
Closed access
AJAdrian E. Jimenez
Adrian E. Jimenez
PSPavan P. Shah
Pavan P. Shah
AKAdham M. Khalafallah
Adham M. Khalafallah
SHSakibul Huq
Sakibul Huq
JPJose Luis Porras
Jose Luis Porras
DMDebraj Mukherjee
Debraj Mukherjee

14 September 2022 in World Neurosurgery
Verified
Journal Article
Closed access
RXRisheng Xu
Risheng Xu
SNSumil K. Nair
Sumil K. Nair
PSPavan P. Shah
Pavan P. Shah
NKNivedha Kannapadi
Nivedha Kannapadi
JMJoshua Materi
Joshua Materi
CBChetan Bettegowda
Chetan Bettegowda

1 March 2022 in World Neurosurgery
Verified
Journal Article
Closed access
AJAdrian E. Jimenez
Adrian E. Jimenez
SCSachiv Chakravarti
Sachiv Chakravarti
SLSophie Liu
Sophie Liu
EWEsther Wu
Esther Wu
OWOren Wei
Oren Wei
DMDebraj Mukherjee
Debraj Mukherjee

1 October 2019 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
PSPavan P. Shah
Pavan P. Shah
CRCarlos G. Romo
Carlos G. Romo
MYMark Yarchoan
Mark Yarchoan
A man in his 50s with nonalcoholic steatohepatitis and hepatocellular carcinoma undergoing checkpoint inhibitor therapy experiences weakness and myalgia. What i

1 April 2021 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
PSP. Shah
P. Shah
MKM. Keller
M. Keller
JMJ. Mathew
J. Mathew
MKM. Kelley
M. Kelley
ENE. Nolley
E. Nolley
SASean Agbor-Enoh
Sean Agbor-Enoh
The need to reduce in-person clinic visits during the COVID-19 pandemic necessitated a significant reduction in traditional lung transplant surveillance with bronchoscopy and clinic-based pulmonary function testing (PFT). We hypothesized that a screening strategy that utilized cell free DNA (CareDx: Allosure), a non-invasive marker of molecular allograft injury, to determine the need for for-cause diagnostics would yield equivalent lung function stability as traditional monitoring using surveillance bronchoscopy and clinic performed PFTs in lung transplant recipients. We compared the change in FEV1, the prevalence of donor-specific HLA antibodies (DSA), and frequency of hospitalization over parallel 6-month timespans in 2 cohorts of LTRs assessed during the 1st 3 years of their transplant. The 1st cohort (N=65) was monitored from 3/2019 to 9/2019 by in-clinic PFT, surveillance bronchoscopy, DSA, and the 2nd cohort (N=73) was monitored from 3/2020-9/2020 with telemedicine, home spirometry, surveillance dd-cfDNA, and DSA testing every 1-3 months. In cohort 2, patients with >10% decline in home FEV1, and/or dd-cfDNA>1% underwent for-cause bronchoscopy and/or further diagnostic evaluation. Surveillance PFTs were conducted once between 7/20 and 9/20 in cohort 2 to assess the stability of lung function. For both cohorts, a minimum interval of 150 days and a maximum interval of 200 days was used for analysis of spirometric change. There were significantly fewer bronchoscopies/patient (pt) in cohort 2 vs cohort 1 (0.91 vs 1.8, p <0.01). Despite reduced bronchoscopic surveillance, the median % change in FEV1 over 6 months did not differ between cohort 1 vs cohort 2 (1.04% vs 1.01 % p =0.51). Further, there was a comparable prevalence of any level HLA-DSA in cohort 1 vs 2 (32% vs 31% p=0.26). The total incidence of hospitalizations was similar in cohort 1 vs 2 (0.98 events/pt. vs. 1.03 events/pt. P=0.25). The use of non-invasive cell-free DNA testing with home spirometry screening appears to yield comparable medium-term allograft outcomes, as compared to conventional clinic-based PFTs and surveillance bronchoscopy. Further multi-center studies are warranted to determine if this approach can reduce invasive procedures while maintaining equivalent outcomes in clinically meaningful parameters.

7 April 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PDF file
KMK. Manrique
K. Manrique
SGS. Griffiths
S. Griffiths
TMT. Miano
T. Miano
LKL. Kalman
L. Kalman
MOM. Oyster
M. Oyster
MSM. Shashaty
M. Shashaty